RZLT
Price:
$5.5
Market Cap:
$307.60M
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is ...[Read more]
Industry
Biotechnology
IPO Date
2013-01-14
Stock Exchange
NASDAQ
Ticker
RZLT
According to Rezolute, Inc.’s latest financial reports and current stock price. The company's current Dividend Yield is 0%. This represents a change of 0% compared to the average of 0% of the last 4 quarters.
The mean historical Dividend Yield of Rezolute, Inc. over the last ten years is 0%. The current 0% Dividend Yield has changed 0% with respect to the historical average. Over the past ten years (40 quarters), RZLT's Dividend Yield was at its highest in in the September 2014 quarter at 0%. The Dividend Yield was at its lowest in in the September 2014 quarter at 0%.
Average
0%
Median
0%
Minimum
0%
Maximum
0%
Discovering the peaks and valleys of Rezolute, Inc. Dividend Yield, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual Dividend Yield = 0%
Minimum Annual Increase = 0%
Minimum Annual Dividend Yield = 0%
Year | Dividend Yield | Change |
---|---|---|
2024 | 0% | 0% |
2023 | 0% | 0% |
2022 | 0% | 0% |
2021 | 0% | 0% |
2020 | 0% | 0% |
2019 | 0% | 0% |
2018 | 0% | 0% |
2017 | 0% | 0% |
2016 | 0% | 0% |
2015 | 0% | 0% |
The current Dividend Yield of Rezolute, Inc. (RZLT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
0%
5-year avg
0%
10-year avg
0%
Rezolute, Inc.’s Dividend Yield is less than Freeline Therapeutics Holdings plc (0%), less than Eledon Pharmaceuticals, Inc. (0%), less than Clene Inc. (0%), less than Reneo Pharmaceuticals, Inc. (0%), less than Larimar Therapeutics, Inc. (0%),
Company | Dividend Yield | Market cap |
---|---|---|
0% | $28.28M | |
0% | $210.18M | |
0% | $48.65M | |
0% | $60.84M | |
0% | $493.86M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rezolute, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Rezolute, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Dividend Yield?
How can you use the Dividend Yield?
What is Rezolute, Inc.'s Dividend Yield?
How is the Dividend Yield calculated for Rezolute, Inc. (RZLT)?
What is the highest Dividend Yield for Rezolute, Inc. (RZLT)?
What is the 3-year average Dividend Yield for Rezolute, Inc. (RZLT)?
What is the 5-year average Dividend Yield for Rezolute, Inc. (RZLT)?
How does the current Dividend Yield for Rezolute, Inc. (RZLT) compare to its historical average?